No Image Available

Nystatin Oral Suspensions/Tablets

Form: Tablets/Suspensions

Strength: Tab: 500,000 units, 1,000,000 units; Sus: 100,000 units/mL, 500,000 units/5 mL

Reference Brands: Mycostatin, Nilstat, Nystop(US)

Category: Anti-fungal

Nystatin tablets and suspension are approved in the EU and US for treating superficial candidiasis. In the EU, formulations like Nystan are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval is based on comprehensive clinical data; generic versions are available. Both regions require detailed dossiers for approval and ongoing pharmacovigilance to ensure safety and efficacy. For expert assistance with regulatory dossiers, registration, and compliance, visit PharmaTradz. We streamline market access for nystatin tablets and suspension, ensuring adherence to European and American standards for safe, effective antifungal therapy.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Nystatin Topical Creams and Ointments

Strength: 100,000 units/g, 100,000–300,000 units/g

Form: Topical Creams and Ointments

Reference Brands: Mycostatin, Nilstat, Nystop(US)

View Details Get Enquiry
Micafungin Intravenous (IV) Powder

Strength: 50 mg, 100 mg/vial

Form: Intravenous (IV) Powder

Reference Brands: Mycamine(US & EU)

View Details Get Enquiry
Anidulafungin injection

Strength: 50 mg/vial

Form: Intravenous (IV) Powder

Reference Brands: Eraxis(US)

View Details Get Enquiry
Caspofungin Intravenous (IV) Powder

Strength: 50 mg/vial, 70 mg/vial

Form: Intravenous (IV) Powder

Reference Brands: Cancidas (US & EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.